HilleVax, Inc. (HLVX)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Ask a question about HilleVax, Inc. (HLVX)
Company Performance

Current Price

as of Oct 16, 2024

$1.82

P/E Ratio

N/A

Market Cap

$90.61M

Description

HilleVax, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing novel vaccines. Its pipeline includes Norovirus and HIL-214. The company was founded by Maurice Hilleman and Tadataka Yamada on March 25, 2020 and is headquartered in Boston, MA.

Metrics

Overview

  • HQBoston, MA
  • SectorHealth Technology
  • IndustryBiotechnology
  • TickerHLVX
  • Price$1.82+1.11%

Trading Information

  • Market Cap$90.61M
  • Float36.82%
  • Average Daily Volume (1m)201,449
  • Average Daily Volume (3m)424,861
  • EPS-$3.39

Company

  • RevenueN/A
  • Rev Growth (1yr)N/A
  • Net Income-$40.67M
  • Gross MarginN/A
  • EBITDA MarginN/A
  • EBITDA-$33.93M
  • EV$517.17M
  • EV/RevenueN/A
  • P/EN/A
  • P/SN/A
  • P/B0.44
Documents